Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa

被引：28
作者：
Ocheretyaner, Eric R. [1 ,2 ]
Park, Tae Eun [3 ]
机构：
[1] LIU Pharm Arnold & Marie Schwartz Coll Pharm & Hl, Div Pharm Practice, Brooklyn, NY USA
[2] Kings Cty Hosp Ctr, Dept Pharm, Brooklyn, NY USA
[3] BronxCare Hlth Syst, Dept Pharm, Bronx, NY USA
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2018年 / 16卷 / 07期
关键词：
Delafloxacin; Pseudomonas aeruginosa; methicillin-resistant Staphylococcus aureus; MRSA; fluoroquinolone; SKIN-STRUCTURE INFECTIONS; IN-VITRO ACTIVITY; ACUTE BACTERIAL SKIN; ACUTE KIDNEY INJURY; STREPTOCOCCUS-PNEUMONIAE; ANTIBACTERIAL ACTIVITIES; NEISSERIA-GONORRHOEAE; HEALTHY-VOLUNTEERS; DOUBLE-BLIND; VANCOMYCIN;
D O I：
10.1080/14787210.2018.1489721
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Introduction: The resistance to current antimicrobial agents, including fluoroquinolones, has continued to grow among various pathogens indicating a need for new antimicrobials to combat multi-drug resistant (MDR) organisms. In June 2017, delafloxacin received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) in adults caused by designated susceptible bacteria.Areas covered: This review describes the pharmacology, pharmacodynamics, pharmacokinetics, product information, efficacy, and safety of delafloxacin.Expert commentary: Delafloxacin is a novel oral and intravenous fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, offering a new option for the treatment of ABSSSI and potentially for complicated urinary tract infections and severe community-acquired bacterial pneumonia.
引用
收藏
页码：523 / 530
页数：8
相关论文
共 39 条
[31]   A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections [J].
O'Riordan, William ;
Mehra, Purvi ;
Manos, Paul ;
Kingsley, Jeff ;
Lawrence, Laura ;
Cammarata, Sue .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 30 :67-73
[32]   In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone [J].
Park, Hee-Soo ;
Kim, Hyun-Joo ;
Seol, Min-Jung ;
Choi, Dong-Rack ;
Choi, Eung-Chil ;
Kwak, Jin-Hwan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2261-2264
[33]   Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers [J].
Patel, Heena ;
Andresen, Arne ;
Vente, Andreas ;
Heilmann, Hans-Dietrich ;
Stubbings, Will ;
Seiberling, Michael ;
Lopez-Lazaro, Luis ;
Pokorny, Rolf ;
Labischinski, Harald .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (09) :4386-4393
[34]   The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin [J].
Paulson, Susan K. ;
Wood-Horrall, Rebecca N. ;
Hoover, Randall ;
Quintas, Megan ;
Lawrence, Laura E. ;
Cammarata, Sue K. .
CLINICAL THERAPEUTICS, 2017, 39 (06) :1182-1190
[35]  
Pfaller MA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02609-16, 10.1128/aac.02609-16]
[36]   Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study [J].
Pullman, J. ;
Gardovskis, J. ;
Farley, B. ;
Sun, E. ;
Quintas, M. ;
Lawrence, L. ;
Ling, R. ;
Cammarata, S. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (12) :3471-3480
[37]   In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance [J].
Soge, Olusegun O. ;
Salipante, Stephen J. ;
No, David ;
Duffy, Erin ;
Roberts, Marilyn C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) :3106-3111
[38]  
Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]
[39]   Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy [J].
Van Bambeke, Francoise .
FUTURE MICROBIOLOGY, 2015, 10 (07) :1111-1123
1234